1. Home
  2. List
Reference Patent

Reference - List

  • 38 Hits
  • Search Condition : Filter (MeSH = Immunotherapy / methods)
Species Resource Title
Mice RBRC09486 IL2/IL15 Signaling Induces NK Cell Production of FLT3LG, Augmenting Anti-PD-1 Immunotherapy.
Human and Animal Cells TUHR10TKB(RCB1275) SLFN11 Drives GM-CSF-mediated M1 Macrophage Polarization and Enhances Immunotherapy Response in Renal Cell Carcinoma.
Human and Animal Cells OP9/N(RCB2926) , OP9/N-DLL1(RCB2927) Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial.
Human and Animal Cells LM8(RCB1450) , MG-63(RCB1890) Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma.
Human and Animal Cells RAW 264(RCB0535) Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages.
Human and Animal Cells Colon-26(RCB2657) Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense.
Mice RBRC09485 The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake.
Human and Animal Cells 293T(RCB2202) , SKW-3(RCB1168) ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of Resistance to Targeted Therapy.
Human and Animal Cells B16/BL6(RCB2638) Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.
Human and Animal Cells HuH-7 Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700.
Human and Animal Cells HSC-2(RCB1945) , HSC-3(RCB1975) , HSC-4(RCB1902) Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer.
Human and Animal Cells Atg5^(+/+)MEF(RCB2710) , Atg5^(-/-)MEF(RCB2711) Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer.
Human and Animal Cells THP-1 Tumor microenvironment-regulated nanoplatforms for the inhibition of tumor growth and metastasis in chemo-immunotherapy.
Human and Animal Cells B16F10(RCB2630) Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist.
Mice RBRC02142 Evaluation of therapeutic PD-1 antibodies by an advanced single-molecule imaging system for human PD-1 microclusters
DNA material CSII-EF-mRFP1 (RDB06387) , mVenus-hGeminin(1/110) / pCSII-EF (RDB15271) , mCherry-hCdt1(30/120)/ pCSII-EF (RDB15273) Intratumoral Anti-PD-1 Nanoformulation Improves Its Biodistribution.
Human and Animal Cells B16 melanoma(RCB1283) , YAC-1(RCB1165) Potent adjuvant effect elicited for tumor immunotherapy by a liposome conjugated pH-sensitive polymer and dendritic cell-targeting Toll-like-receptor ligand.
Human and Animal Cells JLS-V9(RCB2651) Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model.
Human and Animal Cells HOS(RCB0992) Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells.
Human and Animal Cells A549 KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.